article thumbnail

Lannett To Report Fiscal 2021 First-Quarter Financial Results, Host Conference Call On Wednesday, November 4

The Pharma Data

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. A playback of the call will be archived and accessible on the same website for at least three months. About Lannett Company, Inc.

article thumbnail

Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA

The Pharma Data

“At Sandoz, we are constantly looking for ways to meet the changing needs of patients and health care providers,” said Florian Bieber, Global Head Biopharmaceuticals Development, Sandoz. “By About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation

The Pharma Data

As part of the comprehensive submission package to the European Marketing Authorization, Sandoz conducted a Phase I pharmacokinetics (PK) bridging study comparing its approved adalimumab 50 mg/mL 2 with the 100 mg/mL (HCF). It has a leading global portfolio with eight marketed biosimilars and a further 15+ in various stages of development.

article thumbnail

Five Trends in Contract Drug Manufacturing Organisations

Pharmaceutical Technology

For pharma and biotech companies, there are many advantages to partnering with a Contract Development and Manufacturing Organisations (CDMO): they can access more specialized knowledge, state-of-the-art equipment, and qualified staff, as well as reduce their total cost of ownership, all while maintaining speed to market.

article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

is a global pharmaceutical company, working across both developed and emerging markets. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Pfizer Inc.

Sales 98
article thumbnail

‘Right shoring’ API production in Europe

Pharmaceutical Technology

In the 1990s, generic pharmaceutical companies in the European Union (EU) offshored the manufacturing of active pharmaceutical ingredients (API) primarily to China. Koen Berden, executive director of international trade at the International Federation of Pharmaceutical Industries and Associations (EFPIA), in an interview.